Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Glioblastoma 7Congenital Abnormalities 7Lymphoma, Non-Hodgkin 6Lymphoma, Mantle-Cell 6Gliosarcoma 6Burkitt Lymphoma 6Astrocytoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Myeloproliferative Disorders 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Breast Neoplasms 5Brain Neoplasms 5Oligodendroglioma 4Medulloblastoma 4Lymphoma, Large-Cell, Immunoblastic 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Carcinoma, Renal Cell 4Breast Neoplasms, Male 4Blast Crisis 4Anemia, Refractory, with Excess of Blasts 4Waldenstrom Macroglobulinemia 3Sezary Syndrome 3

Interventions

temsirolimus 2Sirolimus 2AZD 6244 2ARQ 197 2veliparib 1sargramostim 1pegfilgrastim 1ixabepilone 1cixutumumab 1belinostat 1Vorinostat 1Topotecan 1Tolbutamide 1Taxes 1Sunitinib 1Rifampin 1Paclitaxel 1Omeprazole 1Midazolam 1Ketoconazole 1Isotretinoin 1Irinotecan 1Introns 1Interferon alpha-2 1Hydroxychloroquine 1Gemcitabine 1Erlotinib Hydrochloride 1Epothilones 1Dextromethorphan 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adult Solid Neoplasm × Vorinostat × Clear all
NCT01281176 2026-04-20

High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
20 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡